Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma

Clinical Nuclear Medicine

Volumn 32, Issue 4, 2007, Pages 271-274

  Karantanis, Dimitrios ^a   O'Neill, Brian P ^a   Subramaniam, Rathan M ^a   Peller, Patrick J ^a   Witte, Robert J ^a   Mullan, Brian P ^a   Wiseman, Gregory A ^a,b  

^a MAYO CLINIC   (United States)

^b Division of Nuclear Medicine   (United States)

Author keywords

FDG; PCNSL; PET CT; Primary CNS lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; FOLINIC ACID; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ABDOMEN; ADULT; ARTICLE; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CASE REPORT; CENTRAL NERVOUS SYSTEM TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG MEGADOSE; HUMAN; HUMAN TISSUE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PELVIS; PERCUTANEOUS BIOPSY; THORAX; ULTRASOUND;

BRAIN NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; IMAGE ENHANCEMENT; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34147163483     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.rlu.0000257269.99345.1b     Document Type: Article

References (14)

1. Central Brain Tumor Registry of the United States. 1995-1999 data; 2002. http://www.cbtrus.org.
2. Loeffler JS, Ervin TJ, Mauch P, et al. Primary lymphomas of the central nervous system: patterns of failure and factors that influence survival. J Clin Oncol. 1985;3:490-494.
3. Plotkin SR, Batchelor TT. Primary nervous-system lymphoma. Lancet Oncol. 2001;2:354-365.
4. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol. 2006;24:1281-1288.
5. Baehring JM, Hochberg FH. Primary lymphoma of the nervous system. Cancer J. 2006;12:1-13.
6. Hochberg FH, Miller DC. Primary central nervous system lymphoma. J Neurosurg. 1988;68:835-853.
7. Miller DC, Hochberg FH, Harris NL, et al. Pathology with clinical correlations of primary central nervous system non-Hodgkin's lymphoma: the Massachusetts General Hospital experience 1958-1989. Cancer. 1994;74:1383-1397.
8. Maher EA, Fine HA. Primary CNS lymphoma. Semin Oncol. 1999;26:346-356.
9. Palmedo H, Urbach H, Bender H, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging. 2006;33:164-168.
10. Rosenfeld SS, Hoffman JM, Coleman RE, et al. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med. 1992;33:532-536.
11. Kuwabara Y, Ichiya Y, Otsuka M, et al. High [18F]FDG uptake in primary cerebral lymphoma: a PET study. J Comput Assist Tomogr. 1988;12:47-48.
12. O'Neill BP, Dinapoli RP, Kurtin PJ, et al. Occult systemic non-Hodgkin's lymphoma in patients initially diagnosed as primary central nervous system lymphoma: how much staging is enough? J Neurooncol. 1995;25:67-71.
13. Ferreri AJM, Reni M, Zoldan MC, et al. Importance of complete staging in non-Hodgkin's lymphoma presenting as a cerebral mass lesion. Cancer. 1996;77:827-833.
14. O'Neill BP, Illig JJ. Primary central nervous system lymphoma. Mayo Clin Proc. 1989;64:1005-20.